When IDH wild-type GBM patients were stratified according to the enrichment of each non-tumor cell type in combination with high or low-quality neoantigens, elevated CD8+ T lymphocytes and high-quality neoantigens emerged as the only features that induced a synergistic effect on survival and classified a subgroup of approximately 10% of IDH wild-type GBM patients with the longest survival in both RNAseq and Agilent microarray datasets (p = 0.0016 and p = 0.0048, respectively; Fig. 4a–f and Supplementary Table 3). This evidence concerns the gene CD8A and glioblastoma.